ni Ronalyn Seminiano Reonico | January 28, 2021
Tutulong ang French drugmaker na Sanofi sa paggawa ng 125 million COVID-19 vaccine doses ng kalaban nitong Pfizer simula sa July upang mapabilis ang produksiyon nito.
Dahil sa huge demand ng COVID-19 vaccines, nahihirapan ang Pfizer at German partner nitong BioNTech na mag-produce ng bakuna.
Ayon kay CEO Paul Hudson, papayagan ng Sanofi na ma-access ng BioNTech ang production facility nila sa Frankfurt.
Aniya, “We have made the decision to support BioNTech and Pfizer in manufacturing their COVID-19 vaccine in order to help address global needs, given that we have the technology and facilities to do so.
Saad naman ni Olivier Bogillot, head ng Sanofi’s French operations, “We had a slight delay on one of our vaccine candidates and decided to use that time to mobilize our production capacities to help with the Pfizer one.”
Samantala, noong nakaraang buwan, ang COVID-19 vaccine candidate na gawa ng Sanofi sa tulong ng British drugmaker na GlaxoSmithKline (GSK) ay hindi nagkaroon ng magandang resulta ngunit plano pa rin nilang mag-produce ng sarili nilang bakuna.
Pahayag pa ni Hudson, “As always, our top priority is to focus our efforts and capabilities on fighting this global pandemic. First and foremost, we will do this by continuing to develop our own COVID-19 vaccines candidates, in parallel with this industrial cooperation.
"Since our main vaccine is a few months late, we asked ourselves how we could be of assistance now.”